Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Axxcess Wealth Management LLC

Axxcess Wealth Management LLC grew its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 4.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 43,884 shares of the company’s stock after purchasing an additional 1,795 shares during the period. Axxcess Wealth Management LLC’s holdings in Recursion Pharmaceuticals were worth $289,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Allspring Global Investments Holdings LLC acquired a new stake in shares of Recursion Pharmaceuticals during the third quarter worth $25,000. Farther Finance Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after purchasing an additional 4,091 shares during the period. GAMMA Investing LLC raised its holdings in shares of Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after purchasing an additional 6,036 shares during the period. Amalgamated Bank raised its holdings in shares of Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares during the period. Finally, San Luis Wealth Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals during the third quarter worth $69,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Recursion Pharmaceuticals

In related news, CFO Michael Secora sold 15,000 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now owns 1,499,631 shares in the company, valued at $11,487,173.46. This represents a 0.99 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Christopher Gibson sold 20,000 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the sale, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at $4,606,442.24. The trade was a 2.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 183,129 shares of company stock worth $1,214,974 in the last 90 days. Corporate insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $6.91 on Friday. The firm has a 50-day moving average price of $6.64 and a 200 day moving average price of $7.62. The firm has a market capitalization of $1.94 billion, a PE ratio of -4.52 and a beta of 0.81. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 52-week low of $5.89 and a 52-week high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The company had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business’s quarterly revenue was up 147.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.43) EPS. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, November 7th. Jefferies Financial Group lowered their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Finally, Leerink Partners lowered their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $9.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.